Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,93 USD | -1,90% |
|
-19,13% | +82,35% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 13,22 mln. 12,34 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -16 mln. -14,93 mln. | Nettowinst (verlies) 2025 * | -21 mln. -19,59 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-2,45
x | K/w-verhouding 2025 * |
-2,51
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 4,97% |
Recentste transcriptie over Chemomab Therapeutics Ltd.
1 dag | -1,90% | ||
1 week | -19,13% | ||
Lopende maand | -13,08% | ||
1 maand | +8,14% | ||
3 maanden | +17,87% | ||
6 maanden | +82,71% | ||
Lopend jaar | +82,35% |
![Extreem 0.7801](/images/extremecours_fleche.png)
![Extreem 0.7801](/images/extremecours_fleche.png)
![Extreem 0.46](/images/extremecours_fleche.png)
![Extreem 0.42](/images/extremecours_fleche.png)
![Extreem 0.42](/images/extremecours_fleche.png)
![Extreem 0.42](/images/extremecours_fleche.png)
![Extreem 0.42](/images/extremecours_fleche.png)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Adi Mor
CEO | Chief Executive Officer | 43 | 22-09-11 |
Sigal Fattal
DFI | Director of Finance/CFO | 53 | 01-01-20 |
Chief Tech/Sci/R&D Officer | 56 | 14-11-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Neil Cohen
BRD | Director/Board Member | 60 | 01-04-20 |
Nissim Darvish
CHM | Chairman | 59 | 16-03-21 |
Claude Nicaise
BRD | Director/Board Member | 71 | 16-03-21 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
20-06-24 | 0,93 | -1,90% | 74 337 |
18-06-24 | 0,948 | +11,54% | 169 073 |
17-06-24 | 0,8499 | -24,79% | 321 870 |
14-06-24 | 1,13 | -1,74% | 68 246 |
13-06-24 | 1,15 | +5,02% | 43 991 |
uitgestelde koers Nasdaq, 20 juni 2024 om 22:30 uur
Meer koersen![Consensus](/images/consensus_flch.gif)
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+82,35% | 13,22 mln. | |
+15,85% | 122 mld. | |
+18,91% | 113 mld. | |
+4,43% | 22,84 mld. | |
-18,63% | 20,72 mld. | |
-13,76% | 16,39 mld. | |
-16,61% | 16,51 mld. | |
-43,53% | 15,83 mld. | |
+1,75% | 13,49 mld. | |
+28,07% | 11,67 mld. |